在活性性结肠炎中对系统性皮质类固醇的反应相关的因素:来自前性多中心试验的结果
Andreas Blesl1, Andrea Borenich2, Hans Peter Gröchenig3
1Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, 8036 Graz, Austria.
Journal of clinical medicine
|July 29, 2023
概括
皮质类固醇对活跃的性结肠炎是有效的,但先前的生物使用会降低反应. 疾病活动影响类固醇依赖,而不是短期有效性.
科学领域:
- 胃肠病学 胃肠病学
- 内部医学 内部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质类固醇经常用于性结肠炎 (UC).
- 在生物疗法时代,它们的有效性正在被重新评估.
- 了解响应的预测因素对于优化UC管理至关重要.
研究的目的:
- 评估系统性皮质类固醇在活跃性性结肠炎中的有效性.
- 确定影响短期反应和类固醇依赖的因素.
- 评估先前生物暴露对皮质类固醇疗效的影响.
主要方法:
- 对103名患有激活性性结肠炎的患者进行了前性多中心研究,该研究启动了皮质类固醇.
- 主要终点:第4周临床反应 (Lichtiger分数下降≥50%).
- 二级终点:综合反应 (临床+生物标志物减少),三个月后的类固醇依赖.
主要成果:
- 73%的人获得了临床反应,68%的综合反应;15%的人依赖类固醇.
- 生物素素的患者表现出比生物素经验丰富的患者更好的反应.
- 过去的吸烟,较低的血红蛋白和生物经验预测了无反应.
结论:
- 疾病活动没有影响短期皮质类固醇反应,但增加了类固醇依赖的风险.
- 之前接触生物药物会对性结肠炎的皮质类固醇反应率产生负面影响.
- 识别非反应预测因素有助于定制性结肠炎治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
355
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
355
Inflammatory Bowel Disease I: Ulcerative Colitis
215
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
215


